Good morning, and welcome to Johnson & Johnson's Second Quarter 2018 Earnings Conference Call. (Operator Instructions) This call is being recorded.
If anyone has any objections, you may disconnect at this time. (Operator Instructions)
I would now like to turn the conference call over to Johnson & Johnson.
You may begin.
Hello.
This is Joe Wolk, and it is my pleasure to welcome you to the investor conference call to review Johnson & Johnson's business results for the second quarter of 2018.
I am pleased to be joined for a discussion by Alex Gorsky, Chairman and Chief Executive Officer.
Also helping us out today is Matt Stuckley, Senior Director of Investor Relations.
As many of you know, this is my first earnings call as Chief Financial Officer.
I am very honored, excited and humbled to assume the role for this great company.
Dominic Caruso leaves a lasting impact on the business in many ways.
I want to personally thank him for his commitment to this transition.
He has been very gracious with his time.
It is great to be surrounded by the many talented and dedicated people of Johnson & Johnson who strive every day to make a positive difference in the lives of all stakeholders outlined in our credo.
And I want to thank you on this webcast for the support and kind words since the announcement.
I look forward to our continued partnership.
As far as naming a new head of Investor Relations, we have many qualified associates to choose from, and we'll be making that announcement in the near future.
Well, as far as the first earnings call, I would hope you agree that the business did their part to help me ease into the role.
Our solid second quarter results, which reflect our highest adjusted operational sales growth since the second quarter of 2016, were driven by the strong double-digit growth in Pharmaceuticals and accelerating sales momentum in our Medical Device Business.
Consumer sales were below our expectations.
However, there were some onetime factors that depressed reported results.
That said, we need to do better in the Consumer segment and have plans in place to accelerate growth in the back half of the year with many new product introductions.
Let me now turn the call over to Matt to cover some housekeeping matters and kick off the sales review.
Thanks, Joe, and hello, everyone.
Regarding today's agenda, I will start by summarizing enterprise sales and earnings per share for the quarter before turning it back to Joe for segment sales highlights.
Alex will then provide his perspective on the company and the health care environment.
Joe will conclude formal remarks discussing our earnings results and guidance considerations as you update your models before we open the call up for your questions.
We anticipate today's webcast to last approximately 75 minutes.
A few logistics before we get into the details.
This review is being made available via webcast accessible through the Investor Relations section of the Johnson & Johnson website at investor.jnj.com.
There, you can also find additional materials including today's presentation and accompanying schedules.
Please note that this morning's presentation includes forward-looking statements.
We encourage you to review this cautionary statement regarding commentary included in today's discussion as well as the company's Form 10-K, which identifies certain factors that could cause the company's actual results to differ materially from those projected.
Our SEC filings, including our 2017 Form 10-K, along with reconciliations of non-GAAP financial measures utilized for today's discussion to the most comparable GAAP measures are all available at investor.jnj.com.
A number of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies.
This slide acknowledges those relationships.
For your reference, here is a slide summarizing notable developments that occurred in the second quarter.
Now on to the results.
Worldwide sales were $20.8 billion for the second quarter of 2018, a 10.6% increase versus the second quarter of 2017.
On an operational basis, sales were up 8.7% as currency had a positive impact of 1.9%.
In the U.S., sales were up 9.4%.
In regions outside the U.S., our operational growth was 7.9%, with the effect of currency exchange rates benefiting our reported OUS results by 3.9 points.
Excluding the net impact of acquisitions and divestitures, operational sales growth was 6.3% worldwide, 5.7% in the U.S. and 6.8% outside the U.S.
Joe will provide the same reference for each segment.
With respect to earnings for the quarter, net earnings were $4 billion, and diluted earnings per share were $1.45 versus $1.40 a year ago.
Excluding amortization expense and special items for both periods, adjusted net earnings for the current quarter were $5.7 billion, and adjusted diluted earnings per share were $2.10, representing increases of 14% and 14.8%, respectively, compared to the same period in 2017.
On an operational basis, adjusted diluted earnings per share grew 11.5%.
Now I will turn the call back to Joe to go over sales highlights by segment.
Joe?
Thank you, Matt.
Beginning with Consumer, I'll now comment on quarterly sales performance by business segment, highlighting items that build upon the slides that are being presented.
Unless otherwise stated, percentages referenced represent operational sales change in comparison to the second quarter of 2017; or, in other words, results that exclude the impact of currency translation.
Worldwide Consumer segment sales totaled $3.5 billion, declining operationally 0.4%.
Excluding the impact of acquisitions and divestitures, mainly the divestiture of the COMPEED business in the Wound Care/Other franchise outside the U.S., total adjusted operational sales growth was 0.9% worldwide.
Performance in the quarter included the onetime impacts of a transportation strike in Brazil and a retail inventory reset for the U.S. baby relaunch.
Taking those items into account, adjusted operational growth would have been consistent with Q1 at approximately 2%.
Our largest consumer franchise, the OTC business, led the segment with above-market performance, growing at 3.7%, driven by share gains across multiple brands.
Analgesics, namely TYLENOL, and digestive products drove the growth.
The beauty franchise grew 1.8% operationally.
As we referenced last quarter, growth in this quarter was expected to be negatively impacted by the Q1 seasonal inventory build of approximately $20 million or 300 basis points in the U.S. related to sun protection products stocking.
This is primarily reflected in NEUTROGENA.
Growth in the quarter was driven by market expansion and share growth for OGX and Dr. Ci Labo, as well as new product introductions in NEUTROGENA outside the U.S.
Oral Care performance in the U.S. saw a solid growth of nearly 5% due to strong LISTERINE consumption from ongoing promotions and new products.
The divestitures of the REACH and REMBRANDT brands negatively impacted worldwide growth by just over 1 point.
The OUS declines are due to competitive pressures.
As I mentioned earlier, Baby Care results were negatively impacted in the quarter by the U.S. baby relaunch as retailers reset their shelves for the new products that started shipping in July.
Results outside the U.S. reflect competitive pressures, partially offset by continued expansion of AVEENO Baby.
Moving on to our Pharmaceutical segment.
Worldwide sales of $10.4 billion grew 17.6%.
Excluding the net impact of the Actelion acquisition, operational adjusted sales growth was 11% worldwide, representing strong above-market growth.
Growth was broadly based, both geographically as well as across therapeutic areas, with double-digit growth in 9 key products, including pro forma sales for UPTRAVI and OPSUMIT obtained in the Actelion acquisition.
The segment was led by the oncology portfolio, which grew globally 39%.
DARZALEX continued its strong performance, growing globally by approximately 68%.
In the U.S., market growth and the strong launch uptake of the 1 prior line indication is resulting in share gains.
Outside the U.S., DARZALEX is experiencing increased penetration and share gains in the 31 EMEA countries in which it is now commercially available, as well as in the Asia Pacific region where it received approval late last year.
IMBRUVICA in the U.S. gained more than 3 points of market share versus prior year across all lines of therapy based on first quarter data, largely driven by share in line 1 chronic lymphocytic leukemia, or CLL.
The CLL market is estimated to have grown approximately 13%.
ZYTIGA had another strong quarter, growing 60% due to the continued market growth of approximately 33% and strong share growth in the metastatic high-risk castration-sensitive prostate cancer indication based on the LATITUDE clinical trial.
Our immunology franchise posted 12% sales growth despite the negative impact of biosimilars on REMICADE sales.
Growth was led by STELARA, up 34%, where we remain very pleased with the uptake of the Crohn's disease indication.
Market share has improved 10 points in Crohn's disease compared to the second quarter of 2017.
REMICADE in the U.S. declined approximately 14%, largely driven by price erosion.
REMICADE has retained approximately 94% of the infliximab volume share.
Lastly, in immunology.
Sales for our newly launched treatment for psoriasis, TREMFYA, totaled $126 million due to strong demand, with over 15,000 patients now on therapy.
TREMFYA has already achieved a 5% share of the psoriasis market.
In neuroscience, our paliperidone palmitate long-acting injectable portfolio grew steadily in all regions, driven by new patient starts and persistency.
Results for the Actelion pulmonary hypertension assets acquired in June 2017 are commented to here on a pro forma basis.
OPSUMIT growth accelerated globally to 16% due to increased share and market growth.
UPTRAVI continues to experience strong demand, with 41% growth in the U.S.
Of note, the dynamic we highlighted in recent quarters regarding an increased level of patients on assistance programs in the U.S. has improved.
As expected, TRACLEER is declining as generics entered the European market during the second half of last year.
Turning our attention to the Medical Devices segment.
Worldwide medical devices sales were $7 billion, growing 1.9%.
Excluding the net impact of acquisitions and divestitures, adjusted operational sales growth was 2.9% worldwide.
We acknowledge there is still work to do here, but this represents our strongest growth since Q3 2016 and is a positive step toward the above-market growth we plan to achieve in 2020, highlighted during our recent Business Review Day.
Operational growth was driven by continued strong performance in Interventional Solutions and Vision as well as improving growth in Surgery.
Within Interventional Solutions, our market leadership in electrophysiology, coupled with our new product offerings in ablation and advanced catheters, continued to propel the overall market and our own growth, which was more than 17% worldwide.
Vision delivered strong growth in both the contact lens and surgical business across key geographies totaling $1.2 billion in sales and worldwide growth of 9.6%.
The contact lens business grew a very healthy 10.5% on the strength of our ACUVUE OASYS and ACUVUE MOIST lines, most notably in our market-leading astigmatism lenses.
In Vision Surgical, worldwide growth of 7.5% was driven by the cataract business, primarily intraocular lenses.
In Orthopaedics, excluding the impact of acquisitions and divestitures, performance was flat to the second quarter of 2017.
In trauma, growth is driven by our newer products like the TFNA femoral nail.
In hips, we continue to be the market leader in the anterior approach and see strong demand for the primary stem ACTIS, although we estimate the market growth was only about 1% in the U.S.
Subsequent to the quarter, we completed the acquisition of assets from Medical Enterprises Distribution, which includes the automated ME1000 Surgical Impactor for use in hip replacement.
The new name for this technology is the KINCISE Surgical Automated System.
In spine and in knees, we are losing share.
However, new product launches in spine and the launch of the ATTUNE Revision System in knees led to improved performance this quarter in both businesses.
Selling days did provide a benefit of approximately 1 point to Orthopaedics growth for the quarter, offsetting the negative impact we noted in the first quarter.
We do not expect selling days to have a material impact on results for the remainder of the year.
Pricing pressure continued to impact all categories in Orthopaedics.
For the quarter, U.S. pure price was negative 5% in spine, negative 3% in hips, negative 2% in knees and negative 1% in trauma.
Within the surgery group, the advanced surgery category was strong, led by growth outside the U.S.
On a worldwide basis, endocutters grew 7% as new products are experiencing strong demand; and biosurgery grew over 8%, driven by topical observable hemostats and biologics.
In general surgery, wound closure grew 5% with growth in all regions as barbed and plus sutures are experiencing strong adoption.
As a final comment regarding the U.S. hospital setting, let me provide utilization trends.
For the first quarter of 2018, we saw a slight increase in hospital admissions of 50 basis points, surgical procedures were down approximately 1% and lab procedures were up about 2.5%.
Our preliminary estimates for the second quarter indicate consistent rates for hospital admissions and surgical procedures, with lab procedure growth lowering to approximately 1.5%.
That concludes the sales highlights for Johnson & Johnson's 2018 second quarter.
It is now my pleasure to turn the call over to Alex Gorsky.
Alex?
Thank you, Joe, and thank all of you for joining our second quarter earnings call and webcast today.
I'm pleased to be here today to discuss our strong performance this second quarter of 2018 and how we are well positioned for the rest of the year and for the future.
Overall, we are very pleased with our financial performance to date, both for the first half of this year as well as in the second quarter.
Our accelerating sales and EPS growth results exceeded consensus estimates.
Following my remarks, Joe will provide deeper insight into how our performance and outlook will impact our full year guidance for 2018.
Before I provide some perspective by business segment, it's important to begin where I usually do, emphasizing that we are always guided by our credo; and this year, we proudly celebrate its 75th anniversary.
Our credo is as relevant today as the day it was written.
Balancing opportunity and responsibility, we're united and inspired by our credo and we live in the responsibilities it outlines each and every day.
It reminds us that our first responsibility is to our customers and patients, and it compels us to deliver on our responsibilities to our employees, our communities, our environment, and last but not least, our shareholders.
And the success we achieved can be directly attributed to our more than 134,000 diverse and talented Johnson & Johnson employees in 60 countries around the world who exhibit our credo values every day in every way.
I am also proud to share that we released our Johnson & Johnson 2017 Health for Humanity Report in June, which highlights how we are preparing for the future, meeting our enduring commitments to create long-term value and positively contributing to society.
This report shares the progress that we're making toward our Health for Humanity 2020 Goals and our UN Sustainable Development Goals.
To complement the report, we also conducted our first-ever Health for Humanity webcast to engage in deeper discussion about the report's contents on environmental, social and governance topics.
This session recording is available on our company website as well.
We recognize that to lead the next frontier of health is a big commitment, but we are ready, willing and able to take on this mission.
Guided by our purpose-driven strategies and values rooted in our credo, we will always seek to put the needs and well-being of the people we serve first.
Additionally, I'd like to highlight that a few weeks ago, we announced Sandi Peterson, Executive Vice President and Group Worldwide Chairman, has decided to retire from Johnson & Johnson effective October 1, 2018.
Sandy joined Johnson & Johnson in 2012, and over her time with our company, she has had responsibility for our Consumer and Medical Device segments in addition to other business functions.
I am sure Sandy will approach the next stage of her life with the same energy that she brought to us.
Please join me in wishing her all the best in this new chapter of her life.
In conjunction with Sandy's decision to retire, we implemented additional management changes that will ensure continued focus on delivering our commitments to all of our stakeholders named in our credo.
Joaquin Duato and Dr. Paul Stoffels have been promoted to Vice Chairman of the Executive Committee.
The role of Vice Chair has traditionally been a part of Johnson & Johnson's leadership structure and in place for most of our company's history.
In the Vice Chair roles, both Joaquin and Paul will leverage their expertise and credo-based leadership broadly across the organization and provide the enterprise with additional strategic counsel, direction and oversight.
I'm also pleased to announce that Ashley McAvoy has been promoted to Executive Vice President, Worldwide Chairman Medical Devices, which includes her continued leadership of our Vision business.
Additionally, Jennifer Taubert will assume responsibility for the Pharmaceutical business.
And both Jennifer and Ashley will be members of the Executive Committee.
Ashley and Jennifer are exceptional long-tenured Johnson & Johnson leaders with proven track records of success and who both embody credo-based leadership.
These and other changes we've made in recent months recognize the deep bench of strength within our company and how we're utilizing the skills of our many talented leaders who will ensure that we continue to create value for our patients, consumers and our shareholders.
Now as you've heard me say on several occasions, innovation has been and will continue to be the cornerstone of every life-saving and life-changing product and solution that we provide to people around the world, and sustaining innovation has been the basis of our success and what has driven our growth and value through the years and will for many years to come.
Increasing investment in innovation is a critical aspect of our strategy and the foundation for our future.
In fact, last year, we ranked #5 in the U.S. and #8 globally across all industries for R&D investment.
And through the first 2 quarters of 2018, due to the benefits of the enacted U.S. tax legislation we highlighted earlier this year, we have increased our investment in R&D by approximately 16%, with the objective of developing new products and solutions that address today's medical needs and anticipate the medical needs of the future.
We continue to invest internally at a very healthy rate, progressing the rich pipelines across our 3 business segments and optimizing the innovative collaboration that happens within the walls of our company.
And as you know, we recognize that good ideas come from everywhere.
This is why we also seek and choose dynamic external partners to innovate with and who can help us unlock new treatments for patients and solutions for our customers.
We are always on the lookout for value-creating opportunities and collaborations; and to this end, we have closed 7 major acquisitions or licensing deals since the beginning of this year.
We also continue to enhance our status as a preferred partner, being agnostic to where the best science and technology resides and aggressively pursuing transformational innovation.
Additionally, we regularly evaluate each of our businesses to determine if they still fit our strategy and our criteria for value creation.
And as you have seen us do consistently, when it makes sense, we undertake a process to consider different ownership where a business might be value-enhancing or if a business might be a better fit in another company's portfolio.
Recently, we announced the acceptance of a binding offer for our LifeScan business and the receipt of a binding offer for our ASP business.
We expect to complete the LifeScan transaction by the end of this year; and should the offer for our ASP business be accepted, the proposed transaction would be expected to close in early 2019, subject to customary conditions and regulatory approvals.
Our activity in both mergers and acquisitions reflects our capital allocation priorities, which have remained consistent and, we believe, proven.
First, as I just highlighted, we prioritize investing in our business at competitive levels, then we allocate capital to drive long-term value by placing a priority on paying dividends to our shareholders.
Next, we deploy capital for value-creating acquisitions.
And finally, we evaluate further opportunities to return value to our shareholders such as through share repurchases.
Johnson & Johnson has the financial strength and cash flow to simultaneously return value to shareholders while, at the same time, continuing to invest in internal and external opportunities that further strengthen our robust enterprise pipeline and drive long-term growth.
Now I want to provide a few highlights about each of our business segments.
But first, I think it's important to emphasize that we continue to think of ourselves as 132-year-old start-up, innovating and executing each and every day to win our customers' and shareholders' trust, confidence and support.
We have a strong sense of urgency.
We are not complacent.
And we are not looking back, we are looking forward and moving forward as fast as the change happening all around us on the global technological, social, economic, political and health care fronts.
We believe Johnson & Johnson is strongly positioned for continued and future growth.
Our Pharmaceutical business has delivered outstanding and sustained performance, growing at an adjusted rate of 11%, inclusive of the impact of negative net price driven by the successful launches and growth of many blockbuster medicines.
It has been an industry leader in all performance measures, including R&D productivity and commercial capabilities.
Earlier this year, we launched ERLEADA, a treatment for patients with non-metastatic, castration-resistant prostate cancer.
This is the second of up to 10 promising new therapeutics that we plan to file or launch by 2021.
Each of these new therapeutics have the potential for more than $1 billion of peak revenue.
Throughout the rest of 2018, we have identified several other key catalysts for growth which focus on: continued patient penetration in our oncology areas of prostate cancer and hematology; a growing immunology portfolio, driven by the continued growth of established brands like STELARA, which is a biologic for the treatment of a number of immune-mediated inflammatory diseases; and new products like TREMFYA, which treats adults living with moderate-to-severe plaque psoriasis.
And this growth is even more impressive when you consider the REMICADE erosion due to biosimilars.
Also, the pulmonary hypertension assets we acquired last year which, by the way, this second quarter represents the strongest quarter we've had to date in this area led by OPSUMIT and UPTRAVI; and the continued solid performance in long-acting injectables in neuroscience, XARELTO and our HIV portfolio.
We are confident that the continued growth of our marketed products and the expected launches from our robust pipeline position us well to outgrow the market for many years to come while offering life-saving or life-changing solutions to give new hope to patients around the world.
Now let me spend some time on our Consumer segment.
As discussed in our Consumer Medical Device business review back in May, I am confident in our strategies to move quickly, to address new market needs with an omnichannel approach from the large box retailers to the e-commerce channels to better serve our consumers.
The consumer second quarter sales growth was disappointing, and as Joe mentioned, this was driven by the impact of some onetime events.
That said, we recognize that we need to perform better here, and we believe we are positioned for strong second half of this year based on our strong underlying consumption data.
Additionally, we are revitalizing our baby business.
In fact, beginning this month, our newly formulated Johnson's Baby products have started to ship to retailers across the United States.
We continue to strengthen and expand our portfolio of iconic, science-based and professionally endorsed products, and we have a number of planned launches in the second half of this year.
We also believe that this will drive top line growth that will be met with even greater bottom line growth as we continue to improve our productivity and margins.
In Medical Devices, we have powerful opportunities for growth across our Orthopaedics, Surgery, Interventional Solutions and Vision businesses.
We have businesses which, again, displayed great strength in the second quarter, such as Vision in electrophysiology, reaching double-digit growth; and biosurgery and endocutters reaching high single-digit growth.
But we fully recognize our progress has not been uniform across the entire portfolio.
There are areas where we must, and we will improve such as in our knee and spine businesses, both of which took positive steps forward in Q2.
While growth was still negative, our knee business improved performance compared to the last quarter, driven by the recent launch of our ATTUNE Revision platform.
Similarly, our spine business improved performance in the second quarter due to the new products we've launched in the space.
We've also increased investments across our Medical Device portfolio in critical capabilities, technologies and solutions that our customers are demanding.
Additionally, we are improving our cadence of innovation and are on track to deliver 15 to 20 major product launches planned for 2018.
We are driving innovation, partnering closer with customers, simplifying operations and focusing on execution, all to meet the needs of customers and patients when, where and how they want their needs to be met.
We believe these drivers will deliver sustainable, above-market growth across the entire breadth of our Medical Devices business starting today, and we are committed to delivering across the portfolio in 2020.
Now as the broadest-based health care company, when we look at the current marketplace, business landscape and external environment, we are often asked about the potential impacts to our business and industries.
Let me address a few of those topics that are in the current headlines.
Regarding the recent St.
Louis talcum powder lawsuit and verdict.
As you know, our baby powder is a trusted product that we sold to families for over 100 years, and Johnson & Johnson is deeply disappointed in this verdict.
Now we remain confident that our products do not contain asbestos and do not cause ovarian cancer, and we intend to pursue all available appellate remedies.
In fact, every verdict against Johnson & Johnson in this court that has gone through the appeals process has been reversed.
Additionally, I want to emphasize that preeminent scientific and regulatory bodies, including the National Cancer Institute, the U.S.
Food and Drug Administration have fully reviewed the full body of scientific evidence on multiple occasions and found that it does not support the allegation that talc causes ovarian cancer.
Like previous appeals, we are confident that there are multiple grounds for reversal of this jury verdict and that, ultimately, the case will be reversed.
Regarding global trade.
As a global company, Johnson & Johnson relies on free trade in open markets to bring its product to patients and consumers around the world.
We continue to work with government officials because fair and equitable trade is in everyone's best interest, not just for companies, but for the consumer.
We will continue to monitor developments very closely on this front as we expect this to be an issue in motion for some time.
Regarding overall health care costs and drug pricing in the United States, I'd like to make a few key points.
First, let me say that we understand why there's such a passionate dialogue on this topic.
We know that people are facing higher out-of-pocket costs when they seek medical care from a hospital, a doctor's office or some other alternative health care provider, and especially when they go to the pharmacy to get medications.
However, as a point of reference, medicines represent 14% of the total health care costs in the United States, and Medical Devices represent 6% of the total health care costs in the United States.
The remaining 80% is accounted for by areas outside of our industry.
I'd also like to emphasize the value derived from innovative medicines has been and continues to be significant in addressing health issues today and reducing morbidity rates in the future.
Furthermore, medicines have contributed greatly to extending life expectancy.
For example, cancer deaths have declined 20% due to pharmaceutical treatments since the '90s.
All these improvements actually offset health care costs in the U.S.
We also believe changes are needed regarding how we cover and pay for medical care and drug treatment therapies in the U.S.
We are working with various partners in the health care system to transform the way health care is paid for so everyone involved is held accountable and rewarded for the value they deliver.
That said, there are a few items that we typically focus on when participating in the health care costs and drug pricing dialogue, and they include, first, a system that rewards innovation.
Companies need to continue to fund research in science and technology and invest in new ideas and new products.
We have the best health care system in the world here in the U.S. and we want a system that allows us to keep it that way.
We also want to see a system that's personalized and value based.
A value-based system begins and ends with the patient at the center of every consideration and is judged on the overall outcome.
Striving to provide patients with convenience and innovative capabilities for health care management, affordable access and coverage choices and personalized health care experiences remains a top priority for Johnson & Johnson.
Second, transparency.
I am really proud that our Pharmaceutical business is taking the lead in transparency in the industry.
We just issued our second annual report on transparency; and as a matter of fact, this year's report shows a decrease in net prices for the products in our portfolio.
Our Janssen U.S.
Transparency Report shows, in 2017, the net impact of price on our Pharmaceutical business was minus 4.6% after rebates and discounts of nearly $15 billion.
And lastly, as we continue to engage in dialogue and develop proposals to contain health care costs, we need to be extremely careful and cognizant about avoiding unintended consequences, which may increase patients' costs further and/or decrease patients' access to affordable and quality health care.
We're really glad that the administration has called for a fact-based dialogue.
We believe a discussion based on facts is a good thing.
It's too early to predict the impact of any potential new federal regulations.
But it's an important issue, we recognize that, and we want to help lead to solutions.
We know that it's our responsibility, and we will continue to unite around efforts that address some of the most critical health and consumer needs of people around the world.
And as we consistently live up to these values, I am very proud and honored to share several industry recognitions for Johnson & Johnson that occurred over the last few months and that further underscore our commitment to make diversity and inclusion an everyday behavior; create an open, supportive and inclusive professional environment where people can bring their whole selves to work; build a global diverse workforce for the future that consistently enhances our business performance and reputation; and ensure that good health is within reach for everyone everywhere.
As a global health care leader, we operate at the intersection of science, technology, speed and change, which enables us to reimagine tomorrow today.
As leaders of this great company, we take that responsibility very seriously.
We believe in a bright and successful future, where virtually anything that can be imagined, can be accomplished through a laser-like focus on innovation, execution and our customers, which ultimately drives superior long-term performance.
And while we're focused on all of this, we also remain committed to fulfilling our credo responsibilities and striving to profoundly change the trajectory of Health for Humanity.
Thank you for your time, interest, engagement and continued support.
I look forward to addressing your questions during the upcoming Q&A, but I will now turn the call back over to Joe, who'll provide more insight on our results for the second quarter as well as additional commentary about our guidance for the remainder of the year.
Joe?
Thanks, Alex.
Since sales have been addressed, I'll comment on second quarter results related to cash, the P&L and then guidance for 2018.
At the end of the quarter, we had approximately $14 billion of net debt, which consists of approximately $18 billion of cash and marketable securities and approximately $32 billion of debt.
Regarding our consolidated statement of earnings for the second quarter of 2018, if you direct your attention to the boxed section of the schedule, you will see we have provided our earnings adjusted to exclude intangible amortization expense and special items.
As referenced in the table of non-GAAP measures, the 2018 second quarter net earnings are adjusted to exclude intangible asset amortization expense and special items of $1.8 billion on an after-tax basis, the largest of which is intangible amortization.
Our adjusted earnings per share is therefore $2.10, exceeding the mean of analyst estimates.
This is an increase of 14.8% versus the second quarter of 2017.
Adjusted EPS on a constant currency basis was $2.04, up 11.5% versus the second quarter 2017.
Highlighting a few items on the statement of earnings.
Gross profit for the quarter decreased by 230 basis points, primarily driven by intangible asset amortization from the Actelion acquisition, partially offset by segment mix.
Selling, marketing and administrative expenses were lower as compared to the second quarter of 2017 by 60 basis points due to leveraging in the Pharmaceutical business, partially offset by investments in Consumer and Medical Devices businesses in support of new product launches.
As you heard from Alex, we prioritize funding for innovation.
Our investment in research and development as a percent of sales was 12.7%, which is higher than the second quarter 2017 as we continue to advance and enhance our pipeline.
Other income and expense was a net expense of $364 million in the quarter compared to net expense of $527 million in the same period last year.
Excluding special items recorded in this line, other income and expense was relatively flat, with a net gain of $461 million in 2018 compared to a net gain of $434 million in the prior year period, primarily reflecting divestiture gains.
Excluding special items, the effective tax rate was 18.5% compared to 20.2% in the same period last year.
This rate is consistent with our expectations as a component of the full year effective tax rate.
The 18.5% rate for the second quarter is the result of current interpretation of certain provisions of the Tax Cuts and Jobs Act, specifically relating to new provisions taxing international income.
We anticipate the U.S.
Treasury to issue regulations later this year.
These anticipated regulations are reflected in our tax rate guidance, which I will provide shortly.
Let's now look at adjusted income before tax by segment.
In the second quarter of 2018, our adjusted income before tax for the enterprise improved 30 basis points versus the second quarter of 2017.
Looking at the adjusted pretax income by segment.
Medical Devices at 27.8% is lower than the previous year, primarily due to acquisitions and new product launches.
Pharmaceutical margins declined by 130 basis points to 43.2%, driven by lower other income.
Consumer margins improved to 25.7% due to divestiture gains, partially offset by an increase in brand marketing investments.
Let me now share some perspectives for you to consider as you refine your financial models for 2018.
Our sales guidance for 2018 continues to include the impact of biosimilars and generics for REMICADE, PROCRIT and TRACLEER.
However, we do not anticipate any impact from generic competition this year for ZYTIGA, RISPERDAL CONSTA, PREZISTA and INVEGA SUSTENNA.
As we've done for several years, our guidance will be based first on a constant currency basis reflecting our results from operations.
This is the way we manage our business, and we believe this provides a good understanding of the underlying performance of our business.
We will also provide an estimate of our sales and EPS results for 2018 with the impact that current exchange rates could have on the translation of those results.
For the full year 2018, we would be comfortable with your models reflecting operational sales of 4.5% to 5.5% for the year, an increase over our previous guidance.
This would result in sales for 2018 on a constant currency basis of approximately $79.9 billion to $80.7 billion.
We expect that operational sales growth, excluding the impact of acquisitions and divestitures, will be between 3.5% and 4.5% for the year, which is also an increase to our previous guidance.
Although we are not predicting the impact of currency movements, utilizing the euro as of last week at $1.17, for the balance of the year, the positive impact of foreign currency translation would be approximately 0.8%.
This is below the rate of $1.23 which we utilized in our previous guidance and results in 120 basis point reduction.
Thus, under this scenario, we expect reported sales to reflect the change in the range of 5.3% to 6.3% for a total expected level of reported sales of approximately $80.5 billion to $81.3 billion.
This is lower than our previous guidance solely due to the change in currency.
Factors for you to consider for the balance of this year are the acceleration of our Consumer and Medical Device businesses as well as the impact of generics and biosimilars that I've mentioned and tougher comparisons on the Pharmaceutical segment as this current wave of above-market growth began in the third quarter of last year.
Our pretax operating margin guidance remains unchanged.
We continue to expect to improve our pretax operating margins by approximately 150 basis points.
For purposes of your models and assuming no major acquisitions or other major uses of cash, I suggest you consider modeling net interest expense of between $500 million and $600 million.
This is lower than previous guidance as we benefit from an increase in interest income from higher rates.
Regarding other income and expense.
As a reminder, this is the account where we record royalty income as well as gains and losses arising from such items as litigation, investments by our development corporation, divestitures, asset sales and write-offs.
We would be comfortable with your models for 2018 reflecting net other income and expense, excluding special items, as a net gain ranging from approximately $1.5 billion to $1.7 billion, which is consistent with our previous guidance.
Moving on to taxes.
Our effective tax rate guidance for 2018, excluding special items, is approximately 17% to 18%, which is a tightening of the range related to our prior guidance.
Taking all of this into consideration, we would be comfortable with adjusted EPS guidance in a range of $7.92 to $8.02 per share on a constant currency basis, reflecting operational or constant currency growth of approximately 8.5% to 9.9%, which is higher than our previous guidance and reflects a tightening of the range due to the underlying strength of the business.
Again, we are not predicting the impact of currency movements.
But to give you an idea of the potential impact on EPS with the euro at $1.17, our reported adjusted EPS will be positively impacted by approximately $0.15 per share, which is lower than our previous guidance of $0.20 per share.
Therefore, our reported adjusted EPS would range from $8.07 to $8.17 per share, reflecting growth of approximately 11.2% at the midpoint.
So in closing, we are pleased with our second quarter results and remain confident about the strength of our business.
Our underlying sales growth, excluding acquisitions and divestitures, is projected to be approximately 3.5% to 4.5%, an acceleration from 2017 and an increase of 1% over our guidance at the start of this year.
Consistent with our principle to grow earnings faster than sales, our guidance for reported adjusted EPS growth is 10.5% to 11.9%, or 11.2% at the midpoint.
This is an increase at the midpoint versus previous guidance, incorporating strong operational performance, partially offset by the impact of the strengthening dollar.
We are confident in our performance, not just for the balance of this year, but beyond.
I will now turn things back over to Matt to open up the Q&A portion of the call.
Great.
Thank you, Joe, and thank you, Alex.
We will now move on to the Q&A portion of today's discussion.
Rob, can you please provide Q&A instructions for those on the line wishing to ask a question?
(Operator Instructions) Your first question comes from the line of Larry Biegelsen with Wells Fargo.
Let me start with one on the guidance and then one on Pharma.
So the first half organic growth, I think it was about 5.3%, excluding acquisitions, divestitures and currency.
And I think the guidance this morning implies second half organic growth of about 2.5%.
So my questions are as follows.
What else besides the comps is leading to the slower second half expected growth?
And what are you expecting directionally for each of the 3 divisions in the second half versus the first half?
And then I'll fit in my second question here on Pharma now.
So ZYTIGA in the U.S. has been driving a lot of your growth in Pharma.
How confident are you that you can continue to drive above-market growth in Pharma in 2019 if you lose exclusivity for ZYTIGA later this year?
Larry, good to hear from you.
I'd like to take the second question first.
With respect to ZYTIGA, if you look at the strong quarter that the Pharmaceutical unit had, let's remove that growth out and still about 8%, well above any market comparator.
So the portfolio is strong.
You look at the uptake of TREMFYA, STELARA for Crohn's, our growth is coming from multiple sources.
So while we're very pleased with ZYTIGA's performance, it's -- we're not dependent upon it.
With respect to guidance, so we have raised the operational growth to a midpoint of 5%.
There's some things that I think that need to be pointed out with respect to the second half.
I want to state upfront, though, we do expect to grow in the second half in our Pharmaceutical unit as well as accelerate, as you heard at our Analyst Day, for Medical Devices and Consumer.
Matter of fact, I think you saw a positive, if not modest, step in this quarter with respect to Medical Devices.
But the comps are pretty significant year-on-year.
If you look at the second half of last year where we had really, I would call it, this new wave of above-market growth at the Pharmaceutical unit, it was dependent upon STELARA doing so well in Crohn's, the launch of TREMFYA, the LATITUDE data came out for ZYTIGA.
The way we looked at it was the first half growth of this year compared to the second half of last year was about 4%, 4% to 5%.
We expect that business to continue to grow going forward.
And again, with the other factors kicking in as well, we think it bodes pretty well for the entire year.
I'd also say we are likely to see a little bit more pronounced effect from generics in the back half of this year, so PROCRIT, CONCERTA and, obviously, TRACLEER in the U.S.
So those are some of the things that I would consider as you look out for the balance of this year.
Your next question comes from Glenn Novarro with RBC Capital Markets.
Alex, I have 2 Medical Device questions for you.
First, toward the tail end of the device meeting, you made the comment about midsize to larger Medical Device acquisitions.
And you commented that you would -- if the opportunity was there and it felt right, that's something that you would consider.
So Alex, I'm wondering if you can elaborate a little bit more on that comment from the Medical Device Day in light of maintaining the AAA rating, in light of over $30 billion of debt on the balance sheet and in light of a new head of Medical Devices, and can you quantify what midsize to large means to you?
And then lastly, on Medical Device strategy, given the fact that you do have a new head of Medical Devices, does anything change in the near term?
And what I'm referring to, it seems like Sandy's strategy to accelerate growth was a function of divesting slow-growth businesses and doing tuck-in deals.
So should we assume that strategy is maintained in the near term?
Glenn, thank you very much for your question.
And look, before I answer both of them, let me also just reiterate some of Joe's earlier comments and congratulate our business leaders, I believe, for producing results this quarter that were very strong and very consistent with a lot of the strategic goals that we had set in place and we discussed over the past several years.
Starting with our Pharmaceutical sector, but even the increased performance, I think, we saw underlying in Medical Devices, particularly in Vision Care and Hospital Medical Devices.
And what we -- clearly have got work to do in Consumer.
We believe we got strong reasons to believe in the back end of the year, given some of the launches that we'll be focusing on as well as other areas of improved execution, that we'll see that delivering at and above-market growth rates.
So I just want to thank all of our employees for making those possible.
Now as it relates to Medical Devices, Glenn, consistent with comments that I've frequently made in the past, we remain very interested in value-creating inorganic growth opportunities in Medical Devices.
We are quite excited about the 15 to 20 launches that we have in place for this year.
And over the past couple of years, I think what we've seen is an uptick in the number of bolt-on acquisitions that we've done.
In fact, just last year, we invested more than $1 billion in our Medical Device group, giving us good new technologies really across almost all of our major platforms.
And of course, with our very strong balance sheet, it also gives us the flexibility to continue to invest going forward.
I won't comment specifically on exactly what size or, obviously, what companies, but when we think that the strategy is right, that it fits with our portfolio, that we feel that, ultimately, we can actually create value based upon the asset and operationalize it and execute, we're ready to do so.
Now regarding the overall strategy of the Medical Device unit, given the change in leadership, I'd like to again thank Sandy for her leadership and for what she contributed, really not only in Medical Devices, but across the other areas of our business.
But also, welcome Ashley who's really a seasoned Johnson & Johnson leader with extensive experience in Medical Devices really for about the past 8 years, both in our Ethicon as well as our Vision Care business, where she's led a very significant turnaround.
But we believe that the underlying strategies of focusing on innovation, i.e., increasing the amount of launches and also bolt-on acquisitions that we've done, we expect that to continue; and improved focus and execution, which has been on place over the last 12 months but will continue going forward.
And we think that we're seeing the early signs that, in fact, that strategy and that plan is playing -- paying off.
As you saw, our HMD growth rate of just about 3.5% for this quarter, and you saw Vision Care continued to grow at an overall rate of about 9%.
So that's the way that I would look at it, and thank you very much for your question.
Your next question comes from the line of Jami Rubin with Goldman Sachs.
Alex, and this is a question for you as well, Joe.
I'd love your views on this.
Corporate simplification is clearly getting rewarded on Wall Street, and J&J has certainly participated in the strategy by selling underperformed businesses.
But investors have actually rewarded much bigger steps to reshape portfolios.
Most recently, Novartis announced decision to spin Alcon, GE's decision to spin its health care business.
Obviously, we've seen massive long-term outperformance in both AbbVie and Zoetis, which were spinouts.
You have been consistent in your view that your credo, 75 years old now, embraces a conglomerate structure.
But just wondering if there's an appetite internally, now with the new CFO in place and with the recent underperformance of the stock, to rethink that conglomerate structure?
After 75 years, is it time to tweak this credo?
Jami, thank you very much for your question.
And look, what I would say is we are always challenging our internal strategy.
And as you and I have talked about in the past that our diversified strategy is not predicated upon our 130-plus-year history, but it's really predicated upon our excitement and our outlook for overall health care and our performance going forward.
As it relates to some of the recent transactions across the business, what I would say here, too, if you look out over a 25-, a 10-, a 15-, a 5-, a 3-, even a 2-year overall performance, what you see is that Johnson & Johnson has outperformed, and we've really managed the business with that kind of a long-term outlook.
I think you've also seen that over the past several years, we've been much more disciplined and focused on pruning our portfolio in appropriate places where, frankly, we didn't feel that we saw significant growth opportunities or perhaps where good companies, good product lines were better suited in someone else's hands as we continue to invest in more promising areas.
And we'll continue to evaluate those kinds of strategies on our model and on our approach going forward.
Thank you very much.
Jami, the only other thing I might add to that and maybe emphasize, as Alex's point, is that we're performance based.
So while our heritage may say we were constructed a certain way, if we don't perform and we don't have the same, I would say, strategies that we're executing upon in terms of being leaders in the markets in which we play, driving earnings a little bit faster than the top line growth and then having the capital allocation priorities that you've become very familiar with, we would challenge that.
And so the nice thing about the transition between Dominic and I is that there doesn't need to be an upheaval of policies or company protocol because the performance is borne out, that it certainly is very strong and it works.
Your next question comes from Vamil Divan with Crdit Suisse.
So a couple on REMICADE, if I could.
Just it looks like it was about a 16% decline in the first quarter if we excluded those onetime impacts, and about 14% this quarter in the U.S.
Is there any sort of sequential changes you're expecting either on price or otherwise as we think about the second half of the year or moving into 2019 just so we can kind of project, obviously, that very important product?
And then the latest that you can share on the lawsuit that Pfizer and others have filed against you guys on some of your contracting strategies.
I think we're waiting for the judge to rule on the motion for dismissal.
Can you just give us a sense of when we expect to hear back from the judge?
And if the case goes forward, when do you think we may ultimately have a decision?
Yes, so with respect to REMICADE performance, yes, I think this quarter was 14%, 16% adjusted in the first quarter.
So I -- we don't see any step change from this point on for the balance of the year.
What I would say is maybe you might see a little bit of increased discounts as contracts come for renewal at the beginning of next year; and there'll be some accrual effect, obviously, in the fourth quarter for that product, but nothing significant.
We still maintain about 94% of the infliximab volume share.
Regarding the lawsuit, which we believe is baseless in its merits, there's really no update on that.
So we'll wait and see, but it's not something that concerns us, given the contracting practices that we employ and how that is on par with others in the industry.
Your next question comes from the line of David Lewis with Morgan Stanley.
Maybe one quick one for Alex and maybe 2 quicks for Joe.
Alex, just coming back to the management changes, if I could.
So we all know Pharma has been the historic value driver for the business.
And I guess, by promoting 2 Pharmaceutical executives to Vice Chairman, is it fair that investors would conclude your management sees Pharma as the driver or the primary driver of shareholder value creation on a go-forward basis?
Why would that be an inappropriate conclusion?
And then 2 quick ones for Joe.
Sure, David.
Thank you very much.
No, I don't think that would be an appropriate conclusion to draw on.
What I would say is, first of all, I'd like to recognize and congratulate the great performance and, frankly, the significant value that's been created on the leadership of Paul and Joaquin and the leadership of our Pharmaceutical business.
But I think it's also important to note that, look, these are very broad seasoned leaders with more than 3 decades of experience.
And for the past several years, Paul was playing a critical role in our Pharmaceutical business.
He's also taking an increasingly more active role across our R&D portfolio.
And so we look forward to having him continue to accelerate the value of our future pipeline and, frankly, the level of science and innovation that we have across Johnson & Johnson.
Joaquin, too, is a very experienced leader who did have some experience outside, actually, in the Medical Device area.
But he's somebody who has, again, a long track record of leading through complex, challenging issues and significant opportunities.
So by expanding his role, we think the impact that he can have in working with Jorge and our Consumer group as well as with our information technology, our supply chain and other areas, will be very positive.
And I think the other important issue here, David, is that with Ashley's promotion, Ashley will continue to report in to me and will report in to me in her new role, maintaining responsibility for Vision Care.
So given her previous experience in Medical Devices, given my experience in Medical Devices, this will allow us to continue to manage our entire portfolio of businesses with very strong leaders across Johnson & Johnson.
And by the way, I'd also be remiss if I didn't recognize Jennifer Taubert, who will now -- is now leading our Pharmaceutical business.
Again, a very experienced, seasoned leader who's been a big part of our Pharmaceutical growth over the past several years, and we really look forward to seeing her upcoming contributions going forward.
Okay, Alex, very clear.
And then Joe, just 2 quick ones from me.
The first is actually, it's the first time, I think, you called out procedure growth as a driver of the AF business in quite some time.
So I'm wondering, are you seeing early benefits from the CABANA trial?
And then just a follow-up on Actelion.
I think that business had a slight decline in the first quarter.
Can you update us on the growth rate of Actelion?
Can you give us the pieces for the overall growth rate in the second quarter?
Sure.
Thanks, David.
So on CABANA, I think that could have a benefit to the market.
It's probably still too early to make that determination that that's driving additional procedures at this point.
With respect to Actelion, I believe if you look at the entire portfolio, it gets it's a little tricky because we had a minor divestiture there.
But I think it was up about 2%.
Where we're really focused on there, as you know though, is OPSUMIT and UPTRAVI where they grew very, very healthy double digits for the quarter.
And again, as I noted in some of the prepared remarks, the dynamic of the Patient Assistance Foundation does not seem to be an overhang.
Thanks for the questions, David.
Your next question comes from the line of Joanne Wuensch with BMO Capital Markets.
Simply there are 2.
In Medical Devices, you pointed out that an extra day added percentage to growth.
Is there anything else, either in Devices, Pharma or Consumer, that need to be called out that may have helped stocking or particular campaigns or et cetera?
No, I think this was a fairly clean quarter with respect to that.
There was some selling days in Medical Devices, primarily on the Orthopaedics side of things that we called out in Q1, which was a hurt.
It comes back as a help this quarter.
And in then of these factors in Consumer which depressed reported results, which we should see come back to us in the back half of this year.
But nothing around gross-to-net or anything of that nature, Joanne.
That's helpful.
And then as my follow-up, I appreciate the progress made in spine and in knees sequentially, but they're still struggling.
And those are markets that even on a good day are probably growing 1% to 2%.
How do we think about them really being additive to the total organization?
And how long does it take to go from a negative growth rate to even a market growth rate?
Yes, Joanne, thank you very much for your question.
And look, we have been disappointed with the performance of both of those segments.
However, we are confident going forward.
And let me just take each.
If we look at our underlying knee business, even just on a sequential basis from first quarter the second quarter, we're seeing underlying improvement.
We believe that that's being driven by the launch of the ATTUNE Revision and -- as well as the extended tibial plate.
We've got other launches regarding the cementless plan in the future.
And look, the data around ATTUNE, whether it's from U.K., Australia, New Zealand or the Michigan registries, remain strong.
And frankly, we put a greater focus on execution with our sales force that we believe will continue to see a positive turnaround in that aspect of our business in the back end of this year.
As you know, with spine, that's been a longer-term issue.
That's been frankly, we believe, a market-driven issue to a very large degree, albeit we have had some dislocation and complexity as we saw the Synthes and DePuy organizations come together that caused some challenge on our sales forces.
And frankly, our innovation cadence slowed down there as well.
I think we're now in a position where we put a much improved focus on stabilizing the sales organization.
Two, we have here, also, a strong cadence of new launches with our interbody cage with other type of guidance systems, as well as some additional nails, plates and screws and other systems that we think are also going to contribute to positive growth as we go through the back end of '18 and into '19.
Thank you.
Your next question comes from Bob Hopkins with Bank of America.
Sorry if I missed this, but just the first question is, wondering if you can just comment on the impact on pricing -- pure pricing on the Pharma business in Q2.
And more importantly, has your outlook for drug pricing for 2018 and beyond changed relative to commentary that you made earlier in the year?
Just looking for an update on this important topic.
Bob, thanks for the question.
So yes, it's an important topic, as Alex referred to in his comments.
So if you look at the stellar results in Pharmaceuticals, where we had 11% adjusted operational growth, that was in light of a price decline of about -- let me see here, about 2% for the quarter.
So it's been 4% year-to-date in terms of negative price, it's 2% for this quarter.
We would expect that to be probably in the realm of about 4% to 6% somewhere this year as we look over the back half of the year and given the results that we've had in the first half.
So again, we continue to act responsibly in this way.
As Alex referenced, our transparency report from last year indicated price down in the U.S. about 4.5%, you're looking at something similar this year.
And Bob, what I would also just add there is that it also just harkens back to the strong underlying volume increases that we're seeing across our portfolio, particularly in oncology and immunology.
But beyond that, our neuroscience group and cardiovascular has remained strong, as well as our infectious disease.
So again, on a very broad-based, volume-driven, which means that, ultimately, we're reaching more patients around the world.
Great.
And then one quick follow up in the trends in Orthopaedics.
I was wondering if you could just clarify on the selling day part.
Was that a global impact for Orthopaedics?
Or is that -- was that more of an impact in the U.S.?
And then I'm just curious, was there any change in your view on kind of orthopedic market growth rates in Q2 versus Q1?
You might want to take this one for...
Thanks, Joe.
So Bob, thanks for the question.
The selling day impact that Joe quoted was global of about 1 point, and that was pretty equal between both the U.S. and outside the U.S.
I think as we look at overall orthopedic market trends in Q2, relatively stable versus what we saw in Q1.
I think in trauma, is one in particular where we did see that market decline a little bit versus the growth that we saw in Q1.
But overall, relatively consistent with the first quarter.
Your next question comes from the line of Danielle Antalffy with Leerink Partners.
Just a follow-up question on the spine business.
It's been pretty weak, and it seems like the market is actually very weak.
And J&J historically has done a lot of reevaluating businesses and getting out of slower-growth businesses that no longer make sense.
Can you talk about whether this even still a good market for J&J?
Is this a business, just based on the recent performance, that could be up for potential divestiture?
And my next question, my follow-up there is, is this a market that might be moving in the direction of stem therapy ultimately?
And what J&J's views are there?
Danielle, thank you very much.
And look, what I would say overall is we still believe that spine is a large, attractive global market.
There's a lot of unmet need because as we all know, as we get older, a lot of the existing technologies don't deliver the same level of clinical outcomes and patient satisfaction, for example, that you might experience with a hip or even a knee replacement.
And look, while we're excited about the progress that we're making and some of the strong cadence of launches and acquisitions, we clearly know that we've got more work to do at the performance of this business.
And the reason for that, frankly, is the continued slowdown of the spine category growth, especially in the U.S.
We had some portfolio gaps, as I mentioned earlier, that we're now closing.
And we had sales force attrition in 2017, which did have a negative impact.
But we think that, that is now stabilized.
So while we still have got work to do, we maintain the #2 position globally.
We think that it's a very strong complement to the rest of our portfolio.
But we are very, very focused on getting that business turned around and moving in the right direction.
Your next question comes from the line of Geoff Meacham with Barclays.
I have a few Pharma questions.
I got one for Joe and then a follow-up for Alex.
So Joe, on PH, UPTRAVI hasn't beaten consensus really until this quarter.
Was there something different in 2Q?
And do you guys view this as the start of a more sustained acceleration of the franchise?
And there's several generics coming into the prostacyclin category this year, what are your guys' expectations on pricing or step edit?
Yes.
So with regards to the performance in the quarter beating consensus, that's probably less relevant for us.
I know it's important for you guys.
But what I would say is it's just probably the Patient Assistance Foundation.
We are seeing, obviously, the impact of the broader reach that Johnson & Johnson has with respect to patient penetration.
Regarding generics coming in later this year, that's part of the guidance in which we've provided.
We'll see how that plays out, and we'll just go from there.
But that is part of our thinking going forward, Geoff.
Geoff, this is Alex.
The other thing that I might add is, look, whenever you do is kind of acquisition, there are certain elements in the transition that you've got to work your way through.
And I think part of what we're seeing, frankly, is now that we have several quarters under our belt, that, that team is really starting to come together.
We're starting to realize the global selling synergies.
I've been particularly impressed with our medical affairs team and the way that we're looking at new opportunities to how do we identify patients earlier, how do we start combination therapy earlier to actually help to potentially stop the progression of the disease and combined with just general executional improvements that we see across the board, that's why it makes us bullish on Actelion going forward.
Okay, that's helpful.
And then, Alex, when you look at the segments within Pharma, obviously, oncology is a standout for growth, but you have neuroscience and cardio metabolic that are laggards.
When you make -- you and the board make capital allocation decisions, does the breadth of Pharma growth really inform your strategy?
I guess I'm trying to figure out how aggressive you want to be on the BD front and whether the categories within Pharma really matter.
Yes.
Look, overall, Geoff, what I would say is we still believe there's a lot of opportunities across the really now 6 different platforms that we have in our Pharmaceutical group.
And it starts basically with unmet need.
I mean, if you look at some of the lower penetration rates of the new categories, for example, in immunology, you still see penetration rates in things like psoriatic -- psoriasis and psoriatic arthritis of only around 35%.
And even in the novel oral anticoagulant class, you still see warfarin at about a 45% share.
So there's a lot of opportunity that we focus on.
I think the other issue for us is that by taking this portfolio approach, not only does it allow us to expand into new patient opportunities and obviously do a lot of medical affairs investment with new indications, but it also enables us to do that in a fairly efficient manner so that we don't have to re-create sales or marketing or reimbursement organizations, but rather, it can be another option in the portfolio.
And frankly, that's why now, for example, if you look in immunology, STELARA is well on its way to becoming our #1 product.
But if you look at TREMFYA, SIMPONI, even with the REMICADE decline in the face of biosimilars, our overall portfolio approach I think is, in fact, really working.
And Geoff, maybe just to pick up on Alex's comment, too, because you called out neuroscience specifically.
The core brands there, the long-acting injectables, are only penetrated to the tune of about 15%.
We know that that's the best way to treat those types of patients, and that portfolio of assets is performing extremely well.
So the reported growth for that particular therapeutic area is impeded by CONCERTA and some declines in Ultram and older products.
I would also point to the excitement we have around esketamine in that particular space.
So we think we'll be following that we're shortly here, certainly by the end of the year.
It's a novel new treatment for patients suffering from depression.
We know that's the #1 cause of suicide here in the United States and globally.
So we think that's going to be a very healthy therapeutic area for us going forward.
Yes, Geoff, just to tag onto that.
Our underlying LAI business in neuroscience is growing at about 12%, we think that category is less than 12% penetrated.
And Joe is exactly right.
If you look at the unmet need in the area of treatment-resistant depression, and frankly, the data -- what the data suggest with the potential for esketamine, we couldn't be more excited for patients or for our business going forward.
Your next question comes from Jayson Bedford with Raymond James.
Just a couple of device-related questions.
And perhaps I missed this, but on the 15 to 20 new product launches in '18, how many of those have you launched already?
And then my second question is just on the margin profile in devices.
The business is generating 30-plus percent margins over the last couple of years.
You've now seen 2 straight quarters of sub-30% margins.
And realize there's a lot of moving parts in this number, but curious as to the source of margin softness.
Is that a function of increased R&D investment?
Is gross margin a little softer?
Any color there would be helpful.
Yes.
So with respect to the new products that we've launched in Medical Devices, I would say, we're probably about 60% of the way there at this point.
Some of these are staggered launches.
If you look at the ATTUNE Revision, we launched it fully here in the U.S. and then it's going to proceed globally.
But I would say we're about 60% out of the way in meeting that commitment for 2018.
With respect to margin comparisons year-on-year, I would think that's going to be related to primarily other income and the lack of divestiture gains that were recognized in the first half of last year versus what we recognized this year.
In terms of R&D investments, I would say that's up slightly.
We are one of the highest investors in terms of absolute dollars in the medical device space.
And gross margin continues to improve from an operational perspective.
There is a little bit of headwind with price, obviously, but in terms of our supply chain, as we announced last quarter, we continue to make refinements there to keep our costs highly competitive to provide patients and hospital systems with greater affordable access.
Your next question is coming from the line of Rick Weiss with Stifel.
Just -- I'll just ask one question, really, this morning, a lot of mine has been answered.
On the -- on Slide 22, you talked about the Medical Device portfolio and growth strategy, Alex.
You highlight the notion that you're focused on maximizing new market growth opportunities and sites of care beyond the hospital.
Not a big deal probably, but are you looking at sites of care beyond the hospital as just simply trends shifting to MH or surgical centers?
Is there something more substantial here that you can do or are thinking about related to home health, digital health, other new initiatives?
Just any color would be very interesting to hear.
Sure, Rick.
Thanks for the question.
And the short answer is yes.
But in particular, in a lot of our conversations and discussions with hospital systems as they're trying to navigate their way through the challenges that they're seeing in the current marketplace, clearly, they're dealing with shifts in care from the traditional hospital operating room to the ambulatory care center, trying to do a better job of managing both preoperative as well as postoperative care.
And those are all areas that, frankly, we think are exciting, not only in terms of the business opportunity, but also in terms of a better position overall for Johnson & Johnson and ultimately improving patient outcomes.
Thank you for the question, Rick, and thanks, everyone, who asked a question today, and apologies to those who we could not get to on time.
However, please don't hesitate to reach out to the Investor Relations team as needed with any follow-ups.
I will turn the call back to Alex for some closing remarks.
Sure.
Well, thank you very much for your continued confidence and support in Johnson & Johnson.
I think you'll agree with me that we had a very strong quarter that's quite consistent with the plans that we've been laying out.
As expected, we have some areas that were particularly strong, others that we need to continue to focus on and improve.
But overall, we're pleased with the progress that we're making.
And again, we appreciate your continued support.
So on behalf of the more than 130,000 employees of Johnson & Johnson around the world who wake up every day trying to help patients and consumers live a longer, healthier and happier life in a credo-based way, thank you very much.
And I look forward to catching up with you later in the year.
Bye for now.
Thank you.
This concludes today's Johnson & Johnson Second Quarter 2018 Earnings Conference Call.
You may now disconnect.
represents a verbatim report of the call.
content of the call has been transcribed accurately and in full.
such changes.
contemplated in the forward-looking statements will be realized.
PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS,
OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS.
MAKING ANY INVESTMENT OR OTHER DECISIONS.
Copyright 2018 Thomson Reuters.
All Rights Reserved.
